中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 97-104.doi: 10.35541/cjd.20200802
中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组
收稿日期:2020-08-14
修回日期:2020-12-20
发布日期:2021-01-29
通讯作者:
王宝玺
E-mail:wangbx@vip.126.com
Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China
Received:2020-08-14
Revised:2020-12-20
Published:2021-01-29
Contact:
Wang Baoxi
E-mail:wangbx@vip.126.com
摘要： 【摘要】 反常性痤疮（AI）/化脓性汗腺炎（HS）是一种因毛囊闭锁导致毛囊皮脂腺单位受累的慢性复发性炎症性皮肤病，好发于顶泌汗腺分布区域，主要表现为青春期开始出现的疼痛性、深在性、炎症性皮损。AI/HS发病与遗传、炎症与免疫、微生物、肥胖及吸烟等因素相关。AI/HS治疗困难，目前的治疗以控制皮损发作频率和发作持续时间、提高患者生活质量为主。医生应根据病情严重程度分级治疗，药物治疗包括抗生素、维A酸类、生物制剂、免疫抑制剂以及抗雄激素药物等，辅助治疗包括外科手术或光电治疗。该共识旨在进一步规范中国AI/HS诊断与治疗方法，提高诊疗水平。
中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组. 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）[J]. 中华皮肤科杂志, 2021,54(2):97-104. doi:10.35541/cjd.20200802
Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China. Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement （2021 version）[J]. Chinese Journal of Dermatology, 2021, 54(2): 97-104.doi:10.35541/cjd.20200802
| ［1］ | Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States［J］. J Am Acad Dermatol, 2013,68（3）:412⁃419. doi: 10.1016/j.jaad.2012.07.027. |
| ［2］ | Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem［J］. J Am Acad Dermatol, 2015,73（5 Suppl 1）:S4⁃S7. doi: 10.1016/j.jaad.2015.07.052. |
| ［3］ | Vinding GR, Miller IM, Zarchi K, et al. The prevalence of inverse recurrent suppuration: a population⁃based study of possible hidradenitis suppurativa［J］. Br J Dermatol, 2014,170（4）:884⁃889. doi: 10.1111/bjd.12787. |
| ［4］ | Garg A, Kirby JS, Lavian J, et al. Sex⁃ and age⁃adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States［J］. JAMA Dermatol, 2017,153（8）:760⁃764. doi: 10.1001/jamadermatol.2017.0201. |
| ［5］ | Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment［J］. Clin Cosmet Investig Dermatol, 2017,10:105⁃115. doi: 10.2147/CCID.S111019. |
| ［6］ | Lee JH, Kwon HS, Jung HM, et al. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population⁃based study［J］. J Eur Acad Dermatol Venereol, 2018,32（10）:1784⁃1790. doi: 10.1111/jdv.15071. |
| ［7］ | Yang JH, Moon J, Kye YC, et al. Demographic and clinical features of hidradenitis suppurativa in Korea［J］. J Dermatol, 2018,45（12）:1389⁃1395. doi: 10.1111/1346⁃8138.14656. |
| ［8］ | Kurokawa I, Hayashi N, Japan Acne Research Society. Questionnaire surveillance of hidradenitis suppurativa in Japan［J］. J Dermatol, 2015,42（7）:747⁃749. doi: 10.1111/1346⁃8138. 12881. |
| ［9］ | Wang B, Yang W, Wen W, et al. Gamma⁃secretase gene mutations in familial acne inversa［J］. Science, 2010,330（6007）:1065. doi: 10.1126/science.1196284. |
| ［10］ | Pink AE, Simpson MA, Desai N, et al. γ⁃Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis［J］. J Invest Dermatol, 2013,133（3）:601⁃607. doi: 10.1038/jid. 2012.372. |
| ［11］ | He Y, Xu H, Li C, et al. Nicastrin/miR⁃30a⁃3p/RAB31 axis regulates keratinocyte differentiation by impairing EGFR signaling in familial acne inversa［J］. J Invest Dermatol, 2019,139（1）:124⁃134. doi: 10.1016/j.jid.2018.07.020. |
| ［12］ | Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa［J］. Br J Dermatol, 2015,173（6）:1431⁃1439. doi: 10. 1111/bjd.14075. |
| ［13］ | Witte⁃Händel E, Wolk K, Tsaousi A, et al. The IL⁃1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction［J］. J Invest Dermatol, 2019,139（6）:1294⁃1305. doi: 10.1016/j.jid.2018.11.018. |
| ［14］ | Thomi R, Cazzaniga S, Seyed Jafari SM, et al. Association of hidradenitis suppurativa with T helper 1/T helper 17 phenotypes: a semantic map analysis［J］. JAMA Dermatol, 2018,154（5）:592⁃595. doi: 10.1001/jamadermatol.2018.0141. |
| ［15］ | Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa［J］. J Invest Dermatol, 2016,136（9）:1768⁃1780. doi: 10.1016/j.jid.2016.04.036. |
| ［16］ | Xu H, He Y, Hui Y, et al. NCSTN mutations in hidradenitis suppurativa/acne inversa do not influence cytokine production by peripheral blood mononuclear cells［J］. Br J Dermatol, 2017,176（1）:277⁃279. doi: 10.1111/bjd.15076. |
| ［17］ | Byrd AS, Carmona⁃Rivera C, O′Neil LJ, et al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa［J］. Sci Transl Med, 2019,11（508）:eaav5908. doi: 10.1126/scitranslmed.aav5908. |
| ［18］ | Kanni T, Zenker O, Habel M, et al. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?［J］. Br J Dermatol, 2018,179（2）:413⁃419. doi: 10.1111/bjd.16428. |
| ［19］ | Giamarellos⁃Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX⁃1 in hidradenitis suppurativa: an open⁃label single⁃arm trial in patients not eligible for adalimumab［J］. Br J Dermatol, 2020,183（1）:176⁃178. doi: 10.1111/bjd.18877. |
| ［20］ | Ring HC, Thorsen J, Saunte DM, et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls［J］. JAMA Dermatol, 2017,153（9）:897⁃905. doi: 10.1001/jamadermatol.2017.0904. |
| ［21］ | Ring HC, Bay L, Nilsson M, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa［J］. Br J Dermatol, 2017,176（4）:993⁃1000. doi: 10.1111/bjd.15007. |
| ［22］ | Ring HC, Emtestam L. The microbiology of hidradenitis suppurativa［J］. Dermatol Clin, 2016,34（1）:29⁃35. doi: 10.1016/j.det.2015.08.010. |
| ［23］ | Lyons AB, Shabeeb N, Nicholson CL, et al. Emerging medical treatments for hidradenitis suppurativa［J］. J Am Acad Dermatol, 2020,83（2）:554⁃562. doi: 10.1016/j.jaad.2020.04.009. |
| ［24］ | Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa［J］. Eur J Pharmacol, 2011,672（1⁃3）:1⁃8. doi: 10.1016/j.ejphar.2011.08. 047. |
| ［25］ | Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa?［J］. Exp Dermatol, 2008,17（5）:455⁃472. doi: 10.1111/j.1600⁃0625.2008.00712_ 1.x. |
| ［26］ | van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes［J］. J Am Acad Dermatol, 2015,73（5 Suppl 1）:S23⁃S26. doi: 10.1016/j.jaad.2015.07.047. |
| ［27］ | Lu L, Lai H, Pan Z, et al. Clinical and histopathological characteristics in patients with scarring folliculitis type of acne inversa［J］. Dermatoendocrinol, 2017,9（1）:e1361575. doi: 10. 1080/19381980.2017.1361575. |
| ［28］ | Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:619⁃644. doi: 10.1111/jdv.12966. |
| ［29］ | Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management［J］. J Am Acad Dermatol, 2019,81（1）:76⁃90. doi: 10.1016/j.jaad.2019.02. 067. |
| ［30］ | Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach［M］//Roenigh R, Roenigh H. Dermatologic Surgery. New York: Marcel Dekker, 1989:729⁃739. |
| ［31］ | Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa［J］. Br J Dermatol, 2003,149（1）:211⁃213. doi: 10.1046/j.1365⁃2133.2003.05390.x. |
| ［32］ | Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity［J］. Br J Dermatol, 2009,161（4）:831⁃839. doi: 10. 1111/j.1365⁃2133.2009.09198.x. |
| ［33］ | Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa［J］. JAMA Dermatol, 2018,154（3）:330⁃335. doi: 10.1001/jamadermatol.2017.5890. |
| ［34］ | Amano M, Grant A, Kerdel FA. A prospective open⁃label clinical trial of adalimumab for the treatment of hidradenitis suppurativa［J］. Int J Dermatol, 2010,49（8）:950⁃955. doi: 10. 1111/j.1365⁃4632.2010.04545.x. |
| ［35］ | Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double⁃blind, placebo⁃controlled crossover trial［J］. J Am Acad Dermatol, 2010,62（2）:205⁃217. doi: 10.1016/j.jaad. 2009.06.050. |
| ［36］ | Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR （hidradenitis suppurativa clinical response）: a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo⁃controlled portion of a phase 2 adalimumab study［J］. J Eur Acad Dermatol Venereol, 2016,30（6）:989⁃994. doi: 10.1111/jdv.13216. |
| ［37］ | Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System （IHS4）, a novel dynamic scoring system to assess HS severity［J］. Br J Dermatol, 2017,177（5）:1401⁃1409. doi: 10. 1111/bjd.15748. |
| ［38］ | Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial［J］. Ann Intern Med, 2012,157（12）:846⁃855. doi: 10.7326/0003⁃4819⁃157⁃12⁃201212180⁃00004. |
| ［39］ | Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa （acne inversa） 2018［J］. Br J Dermatol, 2019,180（5）:1009⁃1017. doi: 10.1111/bjd.17537. |
| ［40］ | Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management［J］. J Am Acad Dermatol, 2019,81（1）:91⁃101. doi: 10.1016/j.jaad.2019.02.068. |
| ［41］ | Zouboulis CC, Bechara FG, Dickinson⁃Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization ⁃ systematic review and recommendations from the HS ALLIANCE working group［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:19⁃31. doi: 10.1111/jdv.15233. |
| ［42］ | Gulliver W, Landells I, Morgan D, et al. Hidradenitis suppurativa: a novel model of care and an integrative strategy to adopt an orphan disease［J］. J Cutan Med Surg, 2018,22（1）:71⁃77. doi: 10.1177/1203475417736290. |
| ［43］ | Alavi A, Lynde C, Alhusayen R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document［J］. J Cutan Med Surg, 2017,21（6）:513⁃524. doi: 10.1177/1203475417716117. |
| ［44］ | Gulliver W, Zouboulis CC, Prens E, et al. Evidence⁃based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa［J］. Rev Endocr Metab Disord, 2016,17（3）:343⁃351. doi: 10.1007/s11154⁃016⁃9328⁃5. |
| ［45］ | Hunger RE, Laffitte E, Läuchli S, et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa［J］. Dermatology, 2017,233（2⁃3）:113⁃119. doi: 10.1159/000477459. |
| ［46］ | Magalhães RF, Rivitti⁃Machado MC, Duarte GV, et al. Consensus on the treatment of hidradenitis suppurativa ⁃ Brazilian Society of Dermatology［J］. An Bras Dermatol, 2019,94（2 Suppl 1）:7⁃19. doi: 10.1590/abd1806⁃4841.20198607. |
| ［47］ | Braunberger TL, Nartker NT, Nicholson CL, et al. Ertapenem ⁃ a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa［J］. Int J Dermatol, 2018,57（9）:1088⁃1093. doi: 10.1111/ijd.14036. |
| ［48］ | Maarouf M, Clark AK, Lee DE, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials［J］. J Dermatolog Treat, 2018,29（5）:441⁃449. doi: 10.1080/09546634.2017.1395806. |
| ［49］ | Miller I, Lynggaard CD, Lophaven S, et al. A double⁃blind placebo⁃controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa［J］. Br J Dermatol, 2011,165（2）:391⁃398. doi: 10.1111/j.1365⁃2133.2011.10339.x. |
| ［50］ | Poveda I, Vilarrasa E, Martorell A, et al. Serum zinc levels in hidradenitis suppurativa: a case⁃control study［J］. Am J Clin Dermatol, 2018,19（5）:771⁃777. doi: 10.1007/s40257⁃018⁃0374⁃5. |
| ［51］ | Hotz C, Sbidian E, Ingen⁃Housz⁃Oro S, et al. Thalidomide in severe hidradenitis suppurativa: a therapeutic option［J］. Acta Derm Venereol, 2019,99（12）:1170⁃1171. doi: 10.2340/00015 555⁃3268. |
| ［52］ | Iwasaki J, Marra DE, Fincher EF, et al. Treatment of hidradenitis suppurativa with a nonablative radiofrequency device［J］. Dermatol Surg, 2008,34（1）:114⁃117. doi: 10.1111/j.1524⁃4725.2007.34025.x. |
| ［53］ | Wilden S, Friis M, Tuettenberg A, et al. Combined treatment of hidradenitis suppurativa with intense pulsed light （IPL） and radiofrequency （RF）［J/OL］. J Dermatolog Treat, 2019:1⁃8（2019⁃10⁃17）. doi: 10.1080/09546634.2019.1677842. https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1677842. |
| ［54］ | Mahmoud BH, Tierney E, Hexsel CL, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long⁃pulsed neodymium:yttrium⁃aluminium⁃garnet laser［J］. J Am Acad Dermatol, 2010,62（4）:637⁃645. doi: 10.1016/j.jaad.2009.07.048. |
| ［55］ | Mordon S. Treating hidradenitis suppurativa with photodynamic therapy［J］. J Cosmet Laser Ther, 2018,20（4）:223⁃228. doi: 10. 1080/14764172.2017.1400169. |
| ［56］ | Emtestam L, Lapins J, Sartorius K. Carbon dioxide laser treatment using methylene blue⁃assisted sinus tract identification in hidradenitis suppurativa［J］. Dermatol Surg, 2017,43（4）:604⁃605. doi: 10.1097/DSS.0000000000001068. |
| ［57］ | Vekic DA, Cains GD. Hidradenitis suppurativa ⁃ management, comorbidities and monitoring［J］. Aust Fam Physician, 2017,46（8）:584⁃588. |
| [1] | 张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767. |
| [2] | 李妍 李明 徐薇 李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263. |
| [3] | 李浩, 王俐 韩宪伟 孙彤 苏芳 孙晓冬 韩莹 杨国玲 刘晓明 王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218. |
| [4] | 《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195. |
| [5] | 王娟娟 陈容 季江 苏文星 魏钰倩 赵莹 尹兴平 苏玉华 施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234. |
| [6] | 吕玲 吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279. |
| [7] | 李锁 向睿宇 李志量 荆可 王媛 张寒梅 冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237. |
| [8] | 包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156. |
| [9] | 温广东 冒丹丹 张原媛 窦沅青 赵培 吴晨雨 张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694. |
| [10] | 李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631. |
| [11] | 焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384. |
| [12] | 王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115. |
| [13] | 欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184. |
| [14] | 王小燕, 张嘉文, 刘韵祎, 刘乙萱, 姜沛彧, 李敏, 陶梦, 许阳. 玫瑰痤疮的皮肤影像学和无创检测技术相关进展[J]. 中华皮肤科杂志, 2022, 0(1): 20200939-e20200939. |
| [15] | 程必红, 窦侠. 慢性痒疹的诊断及分型新进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210130-e20210130. |
|
